Other Sources Fund Early-Stage Alzheimer’s Research As Pharma Favors Later Stages
Could Approval Of Biogen’s Aducanumab Improve Risk Tolerance?
Executive Summary
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.
You may also be interested in...
Patient Support May Have Helped Push Aduhelm Toward Approval
After largely negative advisory committee meeting, a patient group held a listening session with the FDA to be sure their voices were heard during the review of Biogen's aducanumab.
Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab
Lilly reported positive results from a Phase II pivotal trial of donanemab, which targets a modified form of beta-amyloid called N3pG, and has a second pivotal Phase II study under way.
Aducanumab Panel Pushes Back On Rosy FDA Outlook, Could Derail A Swift Approval
An FDA advisory committee panel were critical of the agency’s review package for Biogen's aducanumab, raising uncertainty about the prospects of approval.